InvestorsHub Logo
Followers 18
Posts 1439
Boards Moderated 0
Alias Born 11/01/2018

Re: hnbadger1 post# 398638

Tuesday, 01/17/2023 9:27:17 AM

Tuesday, January 17, 2023 9:27:17 AM

Post# of 459928
ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL
Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results
Plan to Meet with Regulatory Authorities to Determine Next Steps.

Anavex 2-73 Winner...This study result should have a $5 to $10 Billion share price MC.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News